Intestinal dysbiosis and lowered serum lipopolysaccharide-binding protein in Parkinson's disease
Open accessThe DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The intestine is one of the first affected organs in Parkinson's disease (PD). PD subjects show abnormal staining for Escherichia coli and α-synuclein in the colon. METHODS: We recruited 52 PD patients and 36 healthy cohabitants. We measured serum markers and quantified the numbers of 19 fecal bacterial groups/genera/species by quantitative RT-PCR of 16S or 23S rRNA. Although the six most predominant bacterial groups/genera/species covered on average 71.3% of total intestinal bacteria, our analysis was not comprehensive compared to metagenome analysis or 16S rRNA amplicon sequencing. RESULTS: In PD, the number of Lactobacillus was higher, while the sum of analyzed bacteria, Clostridium coccoides group, and Bacteroides fragilis group were lower than controls. Additionally, the sum of putative hydrogen-producing bacteria was lower in PD. A linear regression model to predict disease durations demonstrated that C. coccoides group and Lactobacillus gasseri subgroup had the largest negative and positive coefficients, respectively. As a linear regression model to predict stool frequencies showed that these bacteria were not associated with constipation, changes in these bacteria were unlikely to represent worsening of constipation in the course of progression of PD. In PD, the serum lipopolysaccharide (LPS)-binding protein levels were lower than controls, while the levels of serum diamine oxidase, a marker for intestinal mucosal integrity, remained unchanged in PD. CONCLUSIONS: The permeability to LPS is likely to be increased without compromising the integrity of intestinal mucosa in PD. The increased intestinal permeability in PD may make the patients susceptible to intestinal dysbiosis. Conversely, intestinal dysbiosis may lead to the increased intestinal permeability. One or both of the two mechanisms may be operational in development and progression of PD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Increased gut permeability with intestine α-synuclein accumulation, elevated blood and brain levels of TLR2 and TLR4, and reduced blood levels of the LPS-binding protein have been detected in subjects with”
From The Role of Microbiota-Gut-Brain Axis in Neuropsychiatric and Neurological Disorders (2021) · cites this paper as [413]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As with most of the diseases, PD patients have a different microbiota composition compared to healthy controls or patients affected by other neurological disorders (174–176).”
From The gut-brain axis: how microbiota and host inflammasome influence brain physiology and pathology (2020) · cites this paper as [174]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A clinical study revealed that the level of serum LPS-binding protein in patients with Parkinson's disease was lower than that in controls, indicating that increased intestinal permeability and increased invasion of Gram-negative bacteria leads to an increase in LPS in the circulatory system.148”
From The role of gut dysbiosis in Parkinson’s disease: mechanistic insights and therapeutic options (2021) · cites this paper as [148]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“serum from PD patients contains low levels of LPS binding protein [145,146], which are indicative of a chronic systemic exposure to LPS and gram negative endobacteria [147,148,149]”
From The Interplay between Gut Microbiota and Parkinson’s Disease: Implications on Diagnosis and Treatment (2022) · cites this paper as [145]
In the citing paper
“Reduced number of Prevotella may be associated with decreased mucin synthesis causing increased gut permeability [413].”
From The Role of Microbiota-Gut-Brain Axis in Neuropsychiatric and Neurological Disorders (2021) · cites this paper as [413]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777 · cited 1×
“Postmortem studies of non-PD subjects disclosed incidental α-synuclein-positive Lewy bodies in the gastrointestinal tract, the olfactory system, and the cardiac sympathetic system, which suggests that α-synuclein pathology in PD may start in these tissues [2].”
BackgroundDiet rapidly and reproducibly alters the human gut microbiome
David, L. A., Maurice, C. F., Carmody, R. N., Gootenberg, D. B., Button, J. E., Wolfe, B. E., Ling, A. V., Devlin, A. S., Varma, Y., Fischbach, M. A., et al. (2014) · Nature · doi:10.1038/nature12820 · Cited by 10,100
(2023) · doi:10.1126/science · Cited by 6,063
Gut Microbiota from Twins Discordant for Obesity Modulate Metabolism in Mice
Ridaura, V. K., Faith, J. J., Rey, F. E., Cheng, J., Duncan, A. E., Kau, A. L., Griffin, N. W., Lombard, V., Henrissat, B., Bain, J. R., et al. (2013) · Science · doi:10.1126/science.1241214 · Cited by 3,788 · cited 2×
“Direct evidence supporting the notion that intestinal microbiota determines a clinical phenotype has been recently reported in obesity [9].”
Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030
Dorsey, E. R., Constantinescu, R., Thompson, J. P., Biglan, K. M., Holloway, R. G., Kieburtz, K., Marshall, F. J., Ravina, B. M., Schifitto, G., Siderowf, A., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000247740.47667.03 · Cited by 2,472 · cited 1×
“PD is predicted to affect more than 10 million people worldwide by the year 2030 [1].”
BackgroundGut microbiota are related to Parkinson's disease and clinical phenotype
Scheperjans, F., Aho, V., Pereira, P. A. B., Koskinen, K., Paulin, L., Pekkonen, E., Haapaniemi, E., Kaakkola, S., Eerola‐Rautio, J., Pohja, M., et al. (2015) · Movement Disorders · doi:10.1002/mds.26069 · Cited by 1,968 · cited 3×
“In contrast to Prevotella, the count of Lactobacillus was increased 22-fold in the previous report [10], and 6.”
BackgroundResultOccurrence, Classification, and Biological Function of Hydrogenases: An Overview
Vignais, P. M., & Billoud, B. (2007) · Chemical Reviews · doi:10.1021/cr050196r · Cited by 1,578 · cited 1×
“According to an extensive review of bacterial hydrogenases [25], B.”
BackgroundDisease duration and the integrity of the nigrostriatal system in Parkinson’s disease
Kordower, J. H., Olanow, C. W., Dodiya, H. B., Chu, Y., Beach, T. G., Adler, C. H., Halliday, G. M., & Bartus, R. T. (2013) · Brain · doi:10.1093/brain/awt192 · Cited by 1,286
Colonic bacterial composition in Parkinson's disease
Keshavarzian, A., Green, S. J., Engen, P. A., Voigt, R. M., Naqib, A., Forsyth, C. B., Mutlu, E., & Shannon, K. M. (2015) · Movement Disorders · doi:10.1002/mds.26307 · Cited by 1,281 · cited 1×
“Intestinal microbiota in PD was recently published [10, 11].”
BackgroundForsyth, C. B., Shannon, K. M., Kordower, J. H., Voigt, R. M., Shaikh, M., Jaglin, J. A., Estes, J. D., Dodiya, H. B., & Keshavarzian, A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028032 · Cited by 974 · cited 4×
“In PD, intestinal permeability is increased and the hyperpermeability is correlated with increased intestinal staining for Escherichia coli; nitrotyrosine, a marker for protein oxidation; and α-synuclein [7].”
BackgroundResultInfluential
Cited by
Items 401–500 of 538
Zhang, M. R., Gan, X., Fang, Y., Song, X., Li, Q., & Huang, B. (2024) · Brain Research · doi:10.1016/j.brainres.2024.149032 · Cited by 3
Beisembayeva, M., Shayakhmetova, Y., Сабитовна, М. Ш., Li, I., Yakupov, E. Z., Kaiyrzhanov, R. B., & Grigolashvili, M. A. (2025) · International Journal of Clinical Practice · doi:10.1155/ijcp/5511146 · Cited by 2
“Te most inconsistent fnding was for Bacteroides fragilis , which increased in one study [51] and decreased in another [53].”
InfluentialSadegh, H. R., & Choi, J. P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178622 · Cited by 2
“…with various neurological disorders, such as Parkinson’s disease, multiple sclerosis, ASD, AD, Rett syndrome, neuromyelitis optica, amyotrophic lateral sclerosis, and epilepsy, have revealed significant differences in the diversity and abundance of bacterial communities in the gut [94–102].”
Tsai, S.-T., Lai, Z.-L., Lu, M., Walther-Antonio, M. R. S., Hsu, Y.-Y., Chao, D., Chen, C.-Y., Vettleson-Trutza, S. A., Kuo, J. S., Yang, C.-C., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-26312-6 · Cited by 2
“The genus Akkermansia is known for degrading the intestinal mucin layer 39 , which may increase intestinal permeability—a phenomenon reported in PD 40 .”
Elford, J. D., Heesbeen, E. J., van der Plaats, N. A., Garssen, J., Kraneveld, A. D., Groenink, L., & Perez‐Pardo, P. (2026) · npj Parkinson s Disease · doi:10.1038/s41531-025-01236-0 · Cited by 2
“Speci fi cally, Lactobacillus is often reported as being reduced 115,116 .”
Clinical and Pre-Clinical Evidence for Enteric α-Synuclein Involvement in Parkinson's Disease
Kochman, E. M., Akhtar, K., Ali, A., & Shin Damian, S. (2021) · International Journal of Neurodegenerative Disorders · doi:10.23937/2643-4539/1710019 · Cited by 5
Sex Differences and Gut Microbiota Changes in Parkinson’s Disease
Lee, J., & Shin, C. M. (2022) · Springer eBooks · doi:10.1007/978-981-19-0120-1_24 · Cited by 2
Ernesto, J. T., Damásio, C. M., Gontijo, V. S., Gasparotto, J., & Viegas, C. (2023) · Exploration of Neuroprotective Therapy · doi:10.37349/ent.2023.00038 · Cited by 2
Gut microbiome-based dietary intervention in Parkinson disease subject: A case report
Sulthana, A., Paneyala, S., Sindhu, H. S., Narayan, M. K., Hediyal, T. A., Sonali, S., Senthilkumar, A., Dave, P., Mahalakshmi, A. M., Chidambaram, S. B., et al. (2023) · International journal of Nutrition Pharmacology Neurological Diseases · doi:10.4103/ijnpnd.ijnpnd_8_23 · Cited by 2
Mora-Ortiz, M., García-Fernández, H., Pérez‐Martínez, P., & Camargo, A. (2024) · Open Research Europe · doi:10.12688/openreseurope.18568.1 · Cited by 2
Brain Injury and Neuroinflammation of the Gut-Brain Axis in Subjects with Cerebral Palsy
Ferreira, A. C. F. M., Freire, M., Siqueira, V. L., Ferreira, C. D. A., & Santos, M. T. B. R. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.95763 · Cited by 3
Development of Electronic-Nose Technologies for Early Disease Detection Based on Microbial Dysbiosis
Wilson, A. D., & Forse, L. B. (2018) · International Electronic Conference on Sensors and Applications (ECSA) · doi:10.3390/ecsa-5-05832 · Cited by 2
Neurodegenerative Diseases and the Gut Microbiota
Cabré, S., O’Riordan, K. J., & Cryan, J. F. (2022) · Progress in inflammation research · doi:10.1007/978-3-030-91051-8_11 · Cited by 2
Role of the Gut Microbiome and Bacterial Amyloids in the Development of Synucleinopathies
Trubitsina, N. P., Matiiv, A. B., Rogoza, T. M., Zudilova, A. A., Bezgina, M. D., Zhouravleva, G. A., & Bondarev, S. A. (2024) · Biochemistry (Moscow) · doi:10.1134/s0006297924030118 · Cited by 3
Nishiwaki, H., Hamaguchi, T., Ito, M., Ishida, T., Maeda, T., Kashihara, K., Tsuboi, Y., Ueyama, J., Shimamura, T., Mori, H., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.08.07.242453 · Cited by 2
Self-citationWang, J., Guo, H., Qi, W., & Qiao, Z. (2025) · Journal of Microbiology and Biotechnology · doi:10.4014/jmb.2504.04011 · Cited by 1
“According to existing literature reports, the gut microbiota has extensive and finely tuned regulatory effects in intestinal inflammation [1, 2], tumor occurrence [3-5], Parkinson's disease [6-12], and autism spectrum disorder [13-15].”
Therapeutic potential of phytochemicals and role of gut microbiota in neurodegenerative diseases
Gupta, S. K., & Sharma, R. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-36372-6.00014-8 · Cited by 2
Turek, A., Śmierciak, N., Szwajca, M., Karcz, P., Krzyściak, W., Batko, B., Magacz, M. R., Donicz, P., Furman, K., Bryll, A., et al. (2026) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2026.101206 · Cited by 1
“…and depression (Chalubinska-Fendler et al., 2019; Goku-lakrishnan et al., 2022; Dal Santo et al., 2024; Fang et al., 2023; Hasebe et al., 2022; Hasegawa et al., 2015; Heymann et al., 2022; Just et al., 2021; Moreno-Navarrete et al., 2013; Liu et al., 2014; Pastor et al., 2007; Severance et…”
Gupta, J., Chakraborty, A., Bhattacharya, D., Nag, M., Lahiri, D., Elayaperumal, S., Gill, H. S., Rajeev, M., Pandit, S., Sharma, S., et al. (2026) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-026-02402-y · Cited by 1
Of mice and men—The emerging oral–gut–brain axis of health and disease
Kapila, Y. L., & Weisenberger, D. J. (2026) · Periodontology 2000 · doi:10.1111/prd.70064 · Cited by 1
Update Review of the Relationship Between Gut Microbiota and Neurodegenerative Diseases
Wang, Y., Jing, G., Fu, Y., Li, Y., & Wu, C. (2024) · Diseases & Research · doi:10.54457/dr.202401007 · Cited by 1
Dehnow, A. H., & Krishna, M. S. (2020) · Advances in Zoology and Botany · doi:10.13189/azb.2020.080202 · Cited by 2
Nagai, M., Kubo, M., Ando, R., Ikeda, M., Iwamoto, H., Takeda, Y., & Nomoto, M. (2020) · Nutritional Neuroscience · doi:10.1080/1028415x.2020.1760532 · Cited by 2
“addition, the association between fecal flora and PD has been studied [32].”
BackgroundPhysiological Effects of the Hydrogen Molecules
Fukai, Y. (2020) · Springer eBooks · doi:10.1007/978-981-15-7157-2_4 · Cited by 1
Clinical phenotypes and constipation severity in Parkinson’s disease: Relation to Prevotella species
Mekky, J. F., Ahmad, S., Metwali, M., Farouk, S., Monir, S., El-Sayed, A. M. A., & Asser, S. L. (2022) · Microbes and Infectious Diseases /Microbes and Infectious Diseases · doi:10.21608/mid.2022.110401.1218 · Cited by 4
Markers of Bacterial Translocation in Type 2 Diabetes Mellitus
Meheissen, M. A. (2022) · Biomarkers in disease · doi:10.1007/978-3-030-81303-1_49-1 · Cited by 1
Gut Microbiota Changes and Parkinson’s Disease: What Do We Know, Which Avenues Ahead
Hirayama, M., & Ohno, K. (2023) · Healthy ageing and longevity · doi:10.1007/978-3-031-14023-5_13 · Cited by 1
Self-citationVitamin D and Parkinson's disease
Gonçalves, V., Scorza, F. A., de Almeida, A.-C. G., & Scorza, C. A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-89835-5.00031-4 · Cited by 1
Persely, A., Beszedics, B., Pálóczi, K., Piroska, M., Alijanpourotaghsara, A., Strelnikov, D., Vessal, A., Szabó, H., Hernyes, A., Zoldi, L., et al. (2023) · Medicina · doi:10.3390/medicina59101696 · Cited by 1
“A reduced volume of Lachnospiraceae and Rikenellaceae family members was also correlated with AD [41,42].”
BackgroundSiqueira, M. L. R., Esposti, M. J. P. D., dos Santos, H. M., Domann, K. N., Lopes, W. E., & Silva, D. T. D. R. E. (2023) · doi:10.22533/at.ed.9062327094 · Cited by 1
Microbiota intestinal e a intrínseca relação com a Doença de Parkinson
Menezes, C. A. G. P., Cação, J. R., Oliveira, G. V., Mollinar, A. B. P., Marques, J. W. P., Salvador, J. M., Raposo, M. L. C. C., Araújo, L. R. D., CANELAS, V. A. M., Serrão, C. D. A., et al. (2024) · Brazilian Journal of Health Review · doi:10.34119/bjhrv7n2-026 · Cited by 3
Rajeev, A., & Chattopadhyay, I. (2024) · Springer eBooks · doi:10.1007/978-981-99-8803-7_13 · Cited by 1
Probiotics protect against progressive deterioration of motor functions and Parkinson's disease
Kumari, R., Makwana, M., & Hati, S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95735-9.00047-4 · Cited by 1
The impact of microbiological infections on neurodegenerative diseases
Dilawari, R., & Singh, E. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-28822-7.00016-7 · Cited by 1
Ovallath, S., & Sulthana, B. (2018) · Annals of Movement Disorders · doi:10.4103/aomd.aomd_4_18 · Cited by 1
“[35] Histologically, mucosa shows reduction in barrierpromoting proteins and disruption of tight junction proteins, leading to defects in tight junction without gross damage and to the increased interaction between gut microbes and the tissue.[32-34] Levels of αSYN in patients with increased intestinal permeability we…”
BackgroundResultGut/brain Axis and its Role in Parkinson’s Disease Progression
Myers, K. (2019) · doi:10.31274/cc-20240624-807 · Cited by 1
de Castro, T. B. (2020) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) · Cited by 1
腸内フローラ解析システムYakult Intestinal Flora-SCAN(YIF-SCAN)の開発と応用
Tsuji, H. (2018) · KAGAKU TO SEIBUTSU · doi:10.1271/kagakutoseibutsu.56.371
Self-citationThe Human Gut Microbiome A Focus on Health and Disease with Relevance to Neuropsychiatric Disorders
Worth, C. (2020) · doi:10.31274/cc-20240624-1443 · Cited by 2
The contribution of gut microbiota in the pathogenesis of Parkinson’s disease
Farooqui, T. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821039-0.00008-3
Francella, C., & Foster, J. A. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc297
Association between Gut Microbiome and Parkinson's Disease Revealed by Sparse Learning
Chen, M. (2021) · HARVEST (University of Saskatchewan)
Gut Dysbiosis and Neurological Disorders—An Eclectic Perspective
Bostancıklıoğlu, M., & Demir, T. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819265-8.00041-3 · Cited by 1
Interplay between gut bacteria and Parkinson’s disease medication
van Kessel, S. P. (2021) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.182831964
Li, G., & Marlin, M. C. (2018) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.727046232.793530050
Aidy, S. E., van Kessel, S. P., Schwalbe, M., Engen, P. A., Voigt, R. M., Shaikh, M. W., Sanzò, G., McNamara, P., Yerkan, A., Verhagen, L., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1685667/v1
van Kessel, S. P., Schwalbe, M., Engen, P. A., Voigt, R. M., Shaikh, M. W., Sanzo, G., McNamara, P., Yerkan, A., Metman, L. V., Keshavarzian, A., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4113134
Human microbiome and neurological disorders
Saini, V., & Maurya, P. K. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91313-3.00016-7
Markers of Bacterial Translocation in Type 2 Diabetes Mellitus
Meheissen, M. A. (2022) · Biomarkers in disease · doi:10.1007/978-3-031-08014-2_49
ALI, M. A. M., & Ciobica, A. S. (2020) · Annals of the Academy of Romanian Scientists Series on Biological Sciences · doi:10.56082/annalsarscibio.2020.1.45
Vilanova, J. D. C., de Melo, B. R., da Rocha, T. H. L., da Rocha, I. L., Guerra, B. M. M. D., Garcês, T. C. D. C. S., & de Andrade, A. R. O. (2023) · Research Society and Development · doi:10.33448/rsd-v12i5.41454
USO DE TELAS NA PRIMEIRA INFÂNCIA: O DILEMA SOBRE OS IMPACTOS NO DESENVOLVIMENTO NEUROPSICOMOTOR
Abreu, I. F., Filho, A. H. D. C., de Queiroz, I. R. G., & Caixeta, B. S. (2023) · doi:10.22533/at.ed.90623270928
Santos, C. P., & Schiabel, H. (2023) · doi:10.22533/at.ed.9062327097
Medicina: competências técnica, cientifica e ética na área da saúde 2
Neto, B. R. D. S. (2023) · doi:10.22533/at.ed.906232709
A PREPONDERÂNCIA DA OBESIDADE COMO COMPLICAÇÃO DA INFECÇÃO DE COVID-19
Filho, M. L. S., & Silveira, J. S. (2023) · doi:10.22533/at.ed.9062327093
COGNITION AND FALLS IN PATIENTS WITH PARKINSON’S DISEASE
Sousa, N. M. F., Macedo, R. C., Vaz, L. D. O., & Brucki, S. M. D. (2023) · doi:10.22533/at.ed.9062327098
DESVENDANDO O DIAGNÓSTICO TARDIO EM ONCOLOGIA PEDIÁTRICA: UMA ANÁLISE DOS ASPECTOS E IMPACTOS
Leroy, M. Y., Lopes, L. F., Faria, R. F., Faria, T. M. V., Prado, D. L. Q., Hirai, W. Y., & Mançano, B. M. (2023) · doi:10.22533/at.ed.90623270912
DOENÇAS METABÓLICAS E FRUTAS CÍTRICAS
dos Santos, L. S., Recktenwald, R. D. R., Goldemberg, E. B., Malheiros, R. T., Sarmento, S. M. D. M., Schreiner, G. E., Schmitt, E. G., Brites, G. E., Rodrigues, A. C. D. O., Maders, L. T., et al. (2023) · doi:10.22533/at.ed.90623270913
AÇÕES EDUCATIVAS E INCLUSIVAS A INDIVÍDUOS PRIVADOS DE LIBERDADE
Lana, K. M. D. S., Farias, L. C., Chaves, L. S., Soares, K. M., Alvernaz, C. C. D., & Valadão, A. F. (2023) · doi:10.22533/at.ed.9062327095
TRATAMENTOS MINIMAMENTE INVASIVOS EFICAZES PARA OSTEOARTRITE: UMA BREVE REVISÃO DE LITERATURA
Pereira, V. R., & Viera, R. C. (2023) · doi:10.22533/at.ed.90623270925
O USO DE HEMATÓFAGOS NA CIÊNCIA: DA MEDIEVALIDADE ATÉ A ERA CONTEMPORÂNEA COM EXÍMIA SINGULARIDADE
Wenceslau, M. E. D. M., Martins, M. C., Barreiro, B. D. F., Fernandes, J. A., Barbosa, S., & Sá, A. L. B. (2023) · doi:10.22533/at.ed.90623270922
USO DE METILFENIDATO SEM INDICAÇÃO MÉDICA EM ESTUDANTES DE MEDICINA: REVISÃO BIBLIOGRÁFICA
Araújo, A. C. D. S., Longo, B. G., Paludeto, I. L., de Azevedo, L. F., Striolli, L. M., Rodrigueiro, M. J., & Gelaleti, R. B. (2023) · doi:10.22533/at.ed.90623270927
Ventura, L. C., Mello, G. D. O., Neto, M. J. V. S., & de Moura, P. M. M. F. (2023) · doi:10.22533/at.ed.90623270924
CRITERIOS IMAGENOLÓGICOS EN EL DIAGNÓSTICO DE ATELECTASIA
Ochoa, H. P. P., Jácome, L. A. A., Núñez, S. V. R., González, D. D. C., Mora, M. B. A., Gutierrez, L. E. R., Gálvez, L. K. M., Lima, X. J. F., Pedreros, A. D. C., Cuasquer, C. A. A., et al. (2023) · doi:10.22533/at.ed.90623270910
ORIENTAÇÃO FISIOTERAPÊUTICA DOMICILIAR OFERTADA AOS PACIENTES COM DISFUNÇÕES OSTEOMIOARTICULARES
Luciano, B. D., Fonseca, J. D. S., Vieira, J., & Nielsen, M. B. P. (2023) · doi:10.22533/at.ed.90623270921
A FRAÇÃO DE EJEÇÃO REDUZIDA E A TERAPIA DE RESSINCRONIZAÇÃO CARDÍACA
Pereira, A. H., Hernandez, D. P., & Guina, O. D. (2023) · doi:10.22533/at.ed.9062327091
MANEJO NUTRICIONAL NO PACIENTE COM CÂNCER GÁSTRICO SUBMETIDO A GASTRECTOMIA TOTAL: RELATO DE CASO
de Paiva, B. L. G., Cintra, J. F. M., Pereira, N. C. D. A., Lima, J. R. C., Gomes, F. A., da Silva, L. P. J., Morais, E. G. D. S., & Santos, A. M. D. S. (2023) · doi:10.22533/at.ed.90623270919
Santos, L. N., Nogueira, F. P. D. S., Frota, I. J. G., Lima, A. P. P. D., de Meneses, M. C. O. S., Fonseca, N. F., dos Santos, M. H. A., BARBOSA, A. S., de Caldas, P. S. G., Pacheco, L. D. A. S., et al. (2023) · doi:10.22533/at.ed.90623270911
EIXO SNC E INTESTINO: O QUE A CIÊNCIA JÁ SABE SOBRE ESSA IMPORTANTE VIA
Schreiner, G. E., Maders, L. T., Rodrigues, A. C. D. O., Pereira, C. B., Goldemberg, E. B., Recktenwald, R. D. R., Schmitt, E. G., dos Santos, L. S., Brites, G. E., Sarmento, S. M. D. M., et al. (2023) · doi:10.22533/at.ed.90623270914
ESTUDO SOBRE A ANTINOCICEPÇÃO PROMOVIDA PELA INGESTÃO DE CURCUMINA NAS DOSES DE 20, 40 E 80 MG/KG
Guimarães, A. S., Lopes, C. L., Conceição, M. F. M., da Conceição, E. D. V., & de Oliveira, R. (2023) · doi:10.22533/at.ed.90623270916
UM NOVEMBRO NÃO TÃO AZUL: RASTREAMENTO DE CÂNCER E O RISCO À SAÚDE DO HOMEM
Freire, A. C. A., Rabelo, B. R., Saraiva, C. V., Araújo, G. D. S., Fialho, G. D. H., Leonel, J. R., Bandos, L. B., Villela, L. F. V., Silva, P. A., & Silva, V. C. L. (2023) · doi:10.22533/at.ed.90623270926
Gonçalves, B. R., Brandelero, A. C. L., Frohlich, M. E. F., Lajes, N. R., & Costa, P. S. (2023) · doi:10.22533/at.ed.9062327096
COVID-19: PERCEPÇÃO DA SÍNDROME PÓS-COVID EM PACIENTES HIPERTENSOS E DIABÉTICOS
Scandiuzzi, R. D., Fontana, A. H., Fernandes, L. V., de Moura, J. L. C., Oliveira, L. E. G., & Vanz, C. (2023) · doi:10.22533/at.ed.9062327099
RECOMENDAÇÕES SOBRE O USO DE TERAPIA BIOLÓGICA PARA TRATAMENTO DE PSORÍASE DURANTE A GRAVIDEZ
Costa, I. L., Souza, B. D. C., Silva, M. M., Roviello, V. D., & da Costa, A. C. (2023) · doi:10.22533/at.ed.90623270923
HÉRNIA DIAFRAGMÁTICA CONGÊNITA: PANORAMA GERAL E INTERVENÇÕES MÉDICAS
Giuntini, B. T., Rollemberg, A. B. N., Júnior, A. P. M., Figueiredo, A. R. C., de Souza, B. C., Costa, N. B. L. D., & Alves, N. M. M. (2023) · doi:10.22533/at.ed.90623270917
Generalov, V. O., Obodzinskaya, I. E., Русланович, С. Т., Меликсович, Ю. А., Aleksandrenkova, A. A., Larionov, G. V., & Niculina, L. V. (2023) · Psikhiatriya · doi:10.30629/2618-6667-2023-21-5-17-24 · Cited by 4
The Role of the Smallest Molecule Hydrogen Overcoming Ageing-Related Disease
He, W., Rahman, M. H., Mo, C., Vongdouangchanh, A., Kim, C.-S., & Lee, K. (2024) · Advances in biochemistry in health and disease · doi:10.1007/978-3-031-47375-3_15 · Cited by 1
Molecular Changes and Gut-Related Biomarkers in Parkinson’s Disease for Early Detection
Hashish, S. A., & Abdelhameed, A. M. (2024) · Springer eBooks · doi:10.1007/978-981-19-3949-5_7-1
Role of the Gut Microbiome and Bacterial Amyloids in the Development of Synucleinopathies (Review)
Trubitsina, N. P., Matiiv, A. B., Rogoza, T. M., Zudilova, A. A., Bezgina, M. D., Zhouravleva, G. A., & Bondarev, S. A. (2024) · Biochemistry (Moscow) · doi:10.31857/s0320972524030089
Molecular Changes and Gut-Related Biomarkers in Parkinson’s Disease for Early Detection
Hashish, S. A., & Abdelhameed, A. M. (2024) · Springer eBooks · doi:10.1007/978-981-99-7557-0_7
Human microbiome and neuro-developmental disorders
Capirig, C. J., Moncayo, J. A., Paramashivaiah, S. H., Khor, S. B., Ong, B. A., & Garcia, C. A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15435-5.00010-4
Evaluation of serum and fecal parameters in cats with low-grade intestinal T-cell lymphoma (LGITCL)
Gavazza, A., Mangiaterra, S., Galosi, L., Dottori, A., Biagini, L., Pengo, G., Suchodolski, J. S., Cerquetella, M., & Rossi, G. (2024) · Research in Veterinary Science · doi:10.1016/j.rvsc.2024.105521
Role of microbiome gut-brain axis in brain disorders
Parashar, S., Kapoor, D. U., Gautam, R. K., & Thakur, A. K. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-21680-0.00013-4
Dietary fibre responses in microbiota reveal opportunity for disease-specific prebiotic approaches
Chen, T., Cantu-Jungles, T. M., Zhang, B., Yao, T., Lamothe, L. M., Shaikh, M. W., Engen, P. A., Green, S. J., Keshavarzian, A., & Hamaker, B. R. (2025) · Beneficial Microbes · doi:10.1163/18762891-bja00067 · Cited by 3
Intersecting Psychedelic Pharmacology and Gut-Brain Axis Signaling in Neurodegenerative Disorders
Krishna, H. S. (2025) · JUNIOR RESEARCHERS · doi:10.52340/jr.2025.03.03.09
Nápoles-Medina, A. Y., Aguilar-Uscanga, B. R., Nápoles-Medina, B. G., Brand-Rubalcava, P. A., Tejeda-Martínez, A. R., & Flores-Soto, M. E. (2025) · Neurology Perspectives · doi:10.1016/j.neurop.2025.100206 · Cited by 1
Parasympathetic and Sympathetic Nervous System Dysfunction and Monitoring
DePace, N. L., Soloway, S., Yayac, M. F., & Colombo, J. (2025) · Springer eBooks · doi:10.1007/978-3-031-88769-7_13
Das, A., Vivek, V., & Aich, P. (2025) · Discover Immunity. · doi:10.1007/s44368-025-00016-5
The gut microbiota in Parkinson's disease
Cirstea, M. S. (2024) · cIRcle (University of British Columbia) · doi:10.14288/1.0422979
Aho, V. T. E., Houser, M. C., B., P. P. A., Chang, J., Rudi, K., Paulin, L. G., Hertzberg, V., Auvinen, P., Tansey, M. G., & Scheperjans, F. (2021) · Figshare · doi:10.6084/m9.figshare.13787926
Aho, V. T. E., Houser, M. C., B., P. P. A., Chang, J., Rudi, K., Paulin, L. G., Hertzberg, V., Auvinen, P., Tansey, M. G., & Scheperjans, F. (2021) · Figshare · doi:10.6084/m9.figshare.13787920
Aho, V. T. E., Houser, M. C., B., P. P. A., Chang, J., Rudi, K., Paulin, L. G., Hertzberg, V., Auvinen, P., Tansey, M. G., & Scheperjans, F. (2021) · Figshare · doi:10.6084/m9.figshare.13787932
Aho, V. T. E., Houser, M. C., B., P. P. A., Chang, J., Rudi, K., Paulin, L. G., Hertzberg, V., Auvinen, P., Tansey, M. G., & Scheperjans, F. (2021) · Figshare · doi:10.6084/m9.figshare.13787947
Aho, V. T. E., Houser, M. C., B., P. P. A., Chang, J., Rudi, K., Paulin, L. G., Hertzberg, V., Auvinen, P., Tansey, M. G., & Scheperjans, F. (2021) · Figshare · doi:10.6084/m9.figshare.13787935
Zhao, Y., Walker, D. I., Lill, C. M., Bloem, B. R., Darweesh, S. K. L., Pinto‐Pacheco, B., McNeil, B., Miller, G. W., Heath, A. K., Frissen, M., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26605801
Additional file 1 of Study of the gut microbiome in Egyptian patients with Parkinson’s Disease
Mehanna, M., AbuRaya, S., Ahmed, S. M., Ashmawy, G. A. H. O., Ibrahim, A., & AbdelKhaliq, E. (2024) · Figshare · doi:10.6084/m9.figshare.26605954
Camacho, M. (2024) · Apollo (University of Cambridge) · doi:10.17863/cam.108869
Metadata
- Authors
- Hasegawa, S., Goto, S., Tsuji, H., Okuno, T., Asahara, T., Nomoto, K., Shibata, A., Fujisawa, Y., Minato, T., Okamoto, A., Ohno, K., & Hirayama, M.
- Affiliations
- Nagoya University (JP)
- Yakult Central Institute (JP)
- Aichi University of Education (JP)
- Corresponding author
- Ohno, Kinji
- Hirayama, Masaaki
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2015-11-05
- Volume
- 10
- Issue
- 11
- Pages
- e0142164
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4634857
- OpenAlex
- W2097335121
- Cited by
- 523
- References
- 51
- Citations by year
- 2026: 28 · 2025: 38 · 2024: 51 · 2023: 79 · 2022: 70 · 2021: 80 · 2020: 57 · 2019: 41 · 2018: 51 · 2017: 22 · 2016: 6
- FWCI
- 11.44
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- Ministry of Education, Culture, Sports, Science and Technology
- Ministry of Health, Labour and Welfare
- Japan Society for the Promotion of Science (15K09350, 25870317)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Keywords
- Parkinson's disease, gut dysbiosis, lipopolysaccharide-binding protein, intestinal permeability, Lactobacillus, Clostridium coccoides, Bacteroides fragilis, hydrogen-producing bacteria, Lactobacillus gasseri, constipation, diamine oxidase, intestinal mucosal integrity, fecal microbiota, disease progression
- MeSH terms
- Lipopolysaccharide-Binding Protein, Acute-Phase Proteins, Aged, Bacteria, Carrier Proteins, Constipation, DNA, Bacterial, Feces, Female, Humans, Intestinal Mucosa, Male, Membrane Glycoproteins, Parkinson Disease, Permeability, RNA, Ribosomal, 16S, Case-Control Studies, Metagenome, Dysbiosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.